
Evotec expanding at Milton Park campus
According to Evotec, adding a new building by the end of the year, will bring together all the key functions for small molecule discovery and up to...

How microplastic particles get into the body
Microplastic particles exposed to freshwater or saltwater environments for several weeks are about ten times more likely than pristine particles to...

Topas raises €22m in Series B financining
Topas Therapeutics GmbH has closed a €22m (~$26mn) Series B financing round co-led by Vesalius BioCapital III and BioMedPartners with participation...

LSP reports first closing of dementia fund
The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will...

Vifor Pharma in US$100m licence deal with Cara Therapeutics
Under the licence deal with the US company Cara Therapeutics Inc., Swiss Vifor Pharma has acquired the US commercialisation rights for intravenous...

Atriva Therapeutics gets €24m from EIB
According to Atriva Therapeutics, the proceeds allow the company to start Phase II testing of its oral MEK inhibitor ATR-002. In preclinical trails,...

German researchers find reason for remdesivir's inefficiency
“We have come to a simple conclusion,” said Max Planck Director Patrick Cramer at the MPI for Biophysical Chemistry. “Remdesivir does interfere with...